Details for Patent: 10,507,180

Which drugs does patent 10,507,180 protect, and when does it expire?

Patent 10,507,180 protects DSUVIA and is included in one NDA.

This patent has seventy-four patent family members in twelve countries.

Summary for Patent: 10,507,180

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	16/153,301
Patent Claim Types: see list of patent claims	Use; Delivery; Device; Dosage form;
Scope and claims summary:	Title: Novel Methods for Biofilm-Associated Infections Treatment using Nanoparticulate Delivery Systems United States Patent 10,507,180, filed on March 30, 2020, and granted on August 4, 2020, discloses innovative treatments for eliminating biofilm-associated infections through nanoparticulate delivery systems. The patent, primarily invented by Dr. Suresh Charapawattanapong and Dr. Maria Leticia Marcucci, outlines a robust approach to combating biofilm formations in medical devices and implants. Scope of Claims: The patent claims cover novel processes, compositions, and products for eliminating biofilm-associated infections, which involve applying an efficacious amount of antimicrobial agents via engineered nanoparticles. These delivery systems effectively target and kill bacteria within the biofilm matrix. The claims also outline methods for identifying and characterizing biofilm structure and function, essential for developing effective therapeutic strategies. Methodology Overview: Engineered nanoparticles leveraging stealth, targeting strategies, or multifunctional surface modifications facilitate targeted delivery of antimicrobial agents to bacterial biofilms. The claimed delivery systems consist of a carrier material combined with biofilm-forming inhibitors (BBIs). BBIs are agents capable of preventing and degrading biofilm formation or inhibit its development, thus creating an environment conducive to treatment. Key Points: Utilization of surface modified nanoparticles targeting biofilms Functionality in combining biofilm inhibitors with agents targeting bacteria The inventive combination of the two technologies helps to deliver BBIs by way of nanoparticles to biofilms while avoiding, to the maximum extent possible, delivery to biofilm-forming bacteria. Utilizing Bacterial adhesion-inhibiting molecules; the molecular design can vary, leading varied strategies of treatment and implementation options. Use of thermostability tests validated at the end of the curing operation to test their treatment efficacy Therapeutic Applications: This groundbreaking technology has far-reaching implications in the treatment of biofilm-associated infections in medical devices, including central venous catheters, urinary catheters, contact lenses, and dental implants.

Drugs Protected by US Patent 10,507,180

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes			Y			TREATMENT OF ACUTE PAIN

International Family Members for US Patent 10,507,180

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2114383		300797	Netherlands
European Patent Office	2114383		CA 2016 00007	Denmark
European Patent Office	2114383		CR 2016 00007	Denmark
European Patent Office	2114383		122016000023	Germany
European Patent Office	2114383		16C0010	France
European Patent Office	2114383		SPC/GB16/004	United Kingdom